Steven Ferris

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors
    Steven H Ferris
    Alzheimer s Disease Center, Comprehensive Center on Brain Aging, New York University Langone Medical Center, New York, NY 10016, USA
    Clin Interv Aging 8:1007-14. 2013
  2. pmc Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice
    Vjera A Holthoff
    Old Age Psychiatry and Cognitive Neuropsychiatry, University Hospital Carl Gustav Carus, University of Technology, Fetscherstra├če 74, Dresden 01307, Germany
    Alzheimers Res Ther 3:27. 2011
  3. pmc Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
    Philippe Robert
    Memory Center, CHU University of Nice Sophia Antipolis, hopital de Cimiez, 4 av Victoria, 06000 Nice, France
    Alzheimers Res Ther 2:24. 2010
  4. pmc Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    Steven H Ferris
    Alzheimer Disease Center, Centre of Excellence on Brain Aging, New York University Langone Medical Center, 145 East 32nd Street, New York, NY 10016, USA
    Alzheimers Res Ther 3:22. 2011
  5. pmc Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
    Steven Ferris
    Alzheimer s Disease Center, Center of Excellence on Brain Aging, NYU Langone Medical Center, Orangeburg, New York, USA
    Pharmacogenet Genomics 19:635-46. 2009
  6. doi request reprint Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach
    Steven Ferris
    Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, New York 10016, USA
    Gend Med 6:345-55. 2009
  7. doi request reprint Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients
    Steven Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 5:369-74. 2009
  8. doi request reprint Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients
    Steven Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 5:375-9. 2009
  9. ncbi request reprint A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Arch Neurol 63:49-54. 2006
  10. ncbi request reprint The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease
    Nunzio Pomara
    Geriatric Psychiatry Division, Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Bldg 35, Orangeburg, NY 10962, USA
    Neurochem Res 31:585-8. 2006

Detail Information

Publications20

  1. pmc Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors
    Steven H Ferris
    Alzheimer s Disease Center, Comprehensive Center on Brain Aging, New York University Langone Medical Center, New York, NY 10016, USA
    Clin Interv Aging 8:1007-14. 2013
    ....
  2. pmc Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice
    Vjera A Holthoff
    Old Age Psychiatry and Cognitive Neuropsychiatry, University Hospital Carl Gustav Carus, University of Technology, Fetscherstra├če 74, Dresden 01307, Germany
    Alzheimers Res Ther 3:27. 2011
    ..The validity and reliability of ROSA as well as sensitivity to changes due to intervention were examined in an open-label, single-arm, multicenter clinical study in patients with Alzheimer's disease (AD)...
  3. pmc Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
    Philippe Robert
    Memory Center, CHU University of Nice Sophia Antipolis, hopital de Cimiez, 4 av Victoria, 06000 Nice, France
    Alzheimers Res Ther 2:24. 2010
    ....
  4. pmc Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    Steven H Ferris
    Alzheimer Disease Center, Centre of Excellence on Brain Aging, New York University Langone Medical Center, 145 East 32nd Street, New York, NY 10016, USA
    Alzheimers Res Ther 3:22. 2011
    ....
  5. pmc Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
    Steven Ferris
    Alzheimer s Disease Center, Center of Excellence on Brain Aging, NYU Langone Medical Center, Orangeburg, New York, USA
    Pharmacogenet Genomics 19:635-46. 2009
    ....
  6. doi request reprint Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach
    Steven Ferris
    Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, New York 10016, USA
    Gend Med 6:345-55. 2009
    ..Epidemiologic studies have identified several demographic factors, including gender, that may influence the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD)...
  7. doi request reprint Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients
    Steven Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 5:369-74. 2009
    ..The objective of this post hoc analysis was to assess the treatment effects of Memantine on language in patients with moderate to severe AD, using the recently developed Severe Impairment Battery-Language (SIB-L) scale...
  8. doi request reprint Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients
    Steven Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY, USA
    Alzheimers Dement 5:375-9. 2009
    ..Our objective was to create a new scale, based on the language subscale of the Severe Impairment Battery (SIB), as a sensitive and reliable measurement of treatment effects on language performance...
  9. ncbi request reprint A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Arch Neurol 63:49-54. 2006
    ..This study is an extension of a 28-week, randomized, double-blind, placebo-controlled study of memantine in 252 patients with moderate to severe Alzheimer disease...
  10. ncbi request reprint The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease
    Nunzio Pomara
    Geriatric Psychiatry Division, Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Bldg 35, Orangeburg, NY 10962, USA
    Neurochem Res 31:585-8. 2006
    ..However, further studies with age-matched controls should be done to determine possible AD related changes in this response...
  11. ncbi request reprint A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)
    Steven Ferris
    Alzheimer s Disease Center, Silberstein Institute, New York University School of Medicine, New York, NY 10016, USA
    Int J Geriatr Psychiatry 22:448-55. 2007
    ..To determine the safety and efficacy of memantine in treating Age-Associated Memory Impairment (AAMI)...
  12. ncbi request reprint Memantine in moderate-to-severe Alzheimer's disease
    Barry Reisberg
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    N Engl J Med 348:1333-41. 2003
    ..Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease...
  13. doi request reprint Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease
    Richard S Isaacson
    Department of Neurology, Weill Cornell Medical College, New York, NY, USA
    Am J Alzheimers Dis Other Demen 31:270-7. 2016
    ..These findings suggest 13.3 mg/24 h rivastigmine patch demonstrates broad cognitive efficacy across a range of SIB items and domains in patients with severe AD. ..
  14. pmc Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline
    Susan De Santi
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neuropsychology 22:469-84. 2008
    ..These findings indicate that Robust norms improve identification of healthy individuals who will decline and may be useful for selecting at-risk participants for research studies and early interventions...
  15. pmc Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old
    Mary Sano
    Mount Sinai School of Medicine, New York, USA
    Alzheimer Dis Assoc Disord 24:256-63. 2010
    ..This report describes a pilot study to evaluate feasibility of new home-based assessment technologies applicable to clinical trials for prevention of cognitive loss and Alzheimer disease...
  16. ncbi request reprint Mifepristone (RU 486) for Alzheimer's disease
    Nunzio Pomara
    Department of Psychiatry, New York University School of Medicine, USA
    Neurology 58:1436. 2002
  17. ncbi request reprint Earlier onset of Alzheimer disease symptoms in latino individuals compared with anglo individuals
    Christopher M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 62:774-8. 2005
    ....
  18. pmc Neuropsychological and neuropsychiatric prediction of global cognitive status among older Spanish-speaking Hispanics and English-speaking whites
    Elizabeth Guerrero-Berroa
    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    J Geriatr Psychiatry Neurol 27:266-75. 2014
    ..Neuropsychological and depression measures have been found to predict cognitive functioning. We compared these associations among whites and Spanish-speaking Hispanics...
  19. pmc GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90
    John D Carmichael
    Neuroendocrine Unit, Division of Endocrinology, General Clinical Research Center, New York University School of Medicine, New York, NY, USA
    Clin Endocrinol (Oxf) 65:169-77. 2006
    ..To assess the GH response to GHRH-arginine in apparently healthy adults in relation to cardiovascular risk factors...